Navigation Links
New data on hormone therapy must lead to re-evaluation of official guidelines
Date:10/18/2007

As opinion leaders in the field of menopause medicine from various areas in the world, we wish to emphasize the following points concerning postmenopausal hormone therapy:

  1. Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms and estrogen-deficient urogenital symptoms.

  2. The initial interpretation of the Womens Health Initiative (WHI) trial failed to recognize the immense importance of age and years since menopause on outcomes of HT. The potential impact of specific hormonal regimens on safety of HT should be considered as well.

  3. The results of the WHI trial were wrongly extrapolated to the whole postmenopausal population, which led to a major change in recommendations and guidelines on HT.

  4. Based on current knowledge, the balance between the benefits and risks of HT is clearly in favor of use in the early postmenopausal years for symptomatic, healthy women.

  5. All previous studies, including the WHI trial, have demonstrated significant positive effect on bone density and reduction in fracture risk among hormone users.

  6. Estrogen has favorable metabolic and cardioprotective effects in healthy, young postmenopausal women. The results for the age group 5059 years in the WHI estrogen-alone arm support this claim. Estrogen slows the pace of development of atherosclerosis if started in the early postmenopausal period.

  7. HT may be associated with a small increase in risk for breast cancer, if taken long term. Combined estrogenprogestogen therapy probably carries a higher risk than that recorded for estrogen alone. Prevalence of stroke and thromboembolism strongly correlates with age; therefore, the impact of the HT-related increased risk in this respect becomes more important in the late menopause. Low-dose estrogen or the transdermal route of administration may lead to a more favorable risk profile.

  8. Progestins, combined with estrogen, may decrease the magnitude of estrogen-related cardiac benefits, and increase the risk for breast cancer. There are insufficient data to evaluate the possible differences in the incidence of breast cancer using different types and routes of progestin administration.

Based on the above, we call upon the health authorities to review their policies and revise them in view of the new age-related data on HT. Also, the different outcomes of estrogen-alone and estrogen plus progestin therapy should be considered. Overall, the safety profile of HT until age 60 is favorable, and should not preclude women from using HT when appropriate. Issues of quality of life, including mental, emotional, cognitive and sexual function, should have a higher priority while discussing regulatory policies and official guidelines on postmenopausal HT use.


'/>"/>

Contact: Jean Wright
jwright.ims@btopenworld.com
International Menopause Society
Source:Eurekalert

Related medicine news :

1. Thyroid hormone treatment hastens recovery after cardiac surgery
2. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
3. Hormone replacement Therapy a headache
4. Ovarian cancer in relationship with Hormone therapy
5. Evaluating The Risks and Benefits of Hormone Therapy
6. Scientists crack mechanism of Leptin-Obesity Hormone
7. Scientists use plant hormones to fight cancer
8. Use parathyroid hormone to fight brittle bone disease
9. Multiple Sclerosis Can Be Treated By Blocking Fat Hormone
10. Hormone contraceptives lead to bone problems
11. Hormone treatment helps obese people slim down
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
Breaking Medicine Technology: